Royalty Pharma plc
Royalty Pharma plc (RPRX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · RPRX · as of Jun 8, 2026
Key Statistics
Explore Royalty Pharma plc Data
rprx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 100.0%
The RPRX analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $53.75, representing -3.79% downside from the current price of $55.87.
Competitors & Peers
rprx competitorsRPRX
EXEL
FMS
GMAB
HOLX
INCYStock Performance
Full HistoryAbout Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, eva…
what is royalty pharma plc · rprx stock overview · royalty pharma plc company profile · who is royalty pharma plc ceo · rprx NASDAQ · royalty pharma plc headquarters · royalty pharma plc business segments
About Stock Overview & Key Data
Royalty Pharma plc (RPRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 16, 2020. As of the latest trading session, RPRX stock price is $55.87, with a market capitalization of $24.0B. The stock has returned +67.33% over the past 12 months and +44.59% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Royalty Pharma plc stock is Buy, with an average 12-month price target of $53.75. In fiscal year 2025, Royalty Pharma plc reported revenue of $2.4B and net income of $770.9M. For detailed data — including Royalty Pharma plc revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Royalty Pharma plc (RPRX) stock price is $55.87. The stock is traded on NASDAQ under the ticker symbol RPRX. The 52-week range is $33.37 – $56.07.